News
NPCE
4.090
+6.79%
0.260
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 01/16 17:30
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 01/13 17:31
Why Bed Bath & Beyond Shares Are Trading Higher By 17%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga · 01/10 19:11
BRIEF-Neuropace Announces Preliminary Unaudited Fourth Quarter 2022 Revenue
Reuters · 01/09 22:21
NeuroPace provides revenue outlook, appoints new board member
Seeking Alpha · 01/09 21:55
NeuroPace Announces Preliminary Unaudited Q4 Revenue Of $12.8M And FY22 Revenue Of $45.5M
Benzinga · 01/09 21:04
--Morgan Stanley Adjusts Price Target on NeuroPace to $2.50 From $3.50, Maintains Underweight Rating
--Morgan Stanley Adjusts Price Target on NeuroPace to $2.50 From $3.50, Maintains Underweight Rating
MT Newswires · 01/06 10:26
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 01/02 21:30
NeuroPace Feasibility Study of Its RNS System for Lennox-Gastaut Syndrome Now Underway
MOUNTAIN VIEW, Calif., November 30, 2022--NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced that the first patient with Lennox-Gastaut Syndrome (LGS) ...
Business Wire · 11/30/2022 13:00
$10 Million Bet On Canoo? Check Out These 3 Stocks Under $3 Insiders Are Buying
Benzinga · 11/25/2022 14:43
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 11/24/2022 21:31
NeuroPace Files $150 Million Mixed Shelf
NeuroPace Files $150 Million Mixed Shelf
MT Newswires · 11/09/2022 03:57
BRIEF-NeuroPace Reports Third Quarter 2022 Financial Results, Provides A Business Update
Reuters · 11/08/2022 23:11
NeuroPace Sees FY22 Revenue Of $44.5M-$45.5M Compared To Previous Expectation Of $43M-$45M
Benzinga · 11/08/2022 22:02
BRIEF-Neuropace Inc Files For Mixed Shelf Of Up To $150 Mln
Reuters · 11/08/2022 22:00
NeuroPace Q3 EPS $(0.48) Beats $(0.53) Estimate, Sales $11.16M Beat $9.89M Estimate
Benzinga · 11/08/2022 22:00
NeuroPace GAAP EPS of -$0.48 beats by $0.06, revenue of $11.2M beats by $1.31M
Seekingalpha · 11/08/2022 21:12
-- Earnings Flash (NPCE) NEUROPACE Reports Q3 Revenue $11.2M
-- Earnings Flash (NPCE) NEUROPACE Reports Q3 Revenue $11.2M
MT Newswires · 11/08/2022 16:20
Morgan Stanley Maintains Underweight on NeuroPace, Lowers Price Target to $3.5
Morgan Stanley analyst Drew Ranieri maintains NeuroPace (NASDAQ:NPCE) with a Underweight and lowers the price target from $5.5 to $3.5.
Benzinga · 10/11/2022 14:58
--Morgan Stanley Adjusts NeuroPace's Price Target to $3.50 from $5.50, Maintains Underweight Rating
--Morgan Stanley Adjusts NeuroPace's Price Target to $3.50 from $5.50, Maintains Underweight Rating
MT Newswires · 10/11/2022 13:08
More
Webull provides a variety of real-time NPCE stock news. You can receive the latest news about Neuropace Inc through multiple platforms. This information may help you make smarter investment decisions.
About NPCE
NeuroPace, Inc. is a commercial-stage medical device company. The Company is focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. The Company’s novel and differentiated RNS System is the brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source. The Company’s RNS System is a platform that delivers care for patients suffering from drug-resistant epilepsy and offers a personalized solution and outcomes to the patients suffering from other brain disorders. RNS System is a device that records brain activity data and clinicians to monitor patients. RNS System monitors the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is engaged in treating other brain disorders including depression, impulse control disorders, memory disorders, and post-traumatic stress.